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abstract: Patients with mitral valve disease undergoing cerebrovascular surgery face increased inherent risks 
due to their associated cardiac comorbidities. As such, the anaesthetic management of such patients is distinctly 
challenging. Simultaneous consideration of both the cerebrovascular and underlying cardiac conditions determines 
key anaesthetic issues, as fluids and vasopressors or inotropes need to be titrated according to haemodynamic 
variables in order to optimise cerebral blood flow without compromising cardiac function. We report a 45-year-
old female patient with mild mitral stenosis and moderate-to-severe mitral regurgitation who presented to the 
Khoula Hospital, Muscat, Oman, in 2016 following a ruptured anterior communicating artery aneurysm requiring 
urgent surgical intervention. As highlighted in this case, the VolumeView EV1000™ (Edwards Lifesciences, 
Irvine, California, USA) system is a minimially invasive haemodynamic monitor that can help immensely in the 
perioperative management of such patients.
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امللخ�ص: مر�سى ال�سمام املرتايل الذين يخ�سعون جلراحة الدماغ الوعائية يكونون عر�سة خلطر متاأ�سل نتيجة عوامل املرا�سة القلبية 
امل�سرتكة. لذا، فاإن اإدارة التخدير لهوؤالء املر�سى ي�سكل حتديا وا�سحا. النظر يف وقت واحد حلالة الدماغ الوعائية والقلب يحدد ق�سايا 
التخدير االأ�سا�سية، الأن ال�سوائل وروافع التوتر الوعائي اأو موؤثرات التوتر الع�سلي حتتاج اإىل معايرة وفقا ملتغريات ديناميكا الدم من اأجل 
حت�سني الرتوية الدماغية دون التاأثري على وظيفة القلب. نعر�ص حالة مري�سة عمرها 45 عاما م�سابة بت�سيق ب�سيط يف ال�سمام املرتايل 
وقل�ص مرتايل معتدل اإىل �سديد تقدمت اإىل م�ست�سفى خولة، م�سقط، عمان، عام 2016، بعد متزق اأم الدم يف ال�رصيان املو�سل االأمامي والذي 
اأرفن،  �ساين�ص،  )اأدوارد اليف   EV1000 لتدخل جراحي عاجل. مثل ما هو مبني يف هذه احلالة، يعترب جهاز نظام عر�ص احلجم  تطلب 
باجلراحة املحيطة  الفرتة  اأثناء  كثريا  ي�ساعد  والذي  الدم  ديناميكا  ملراقبة  با�سع  غري  جهاز  االأمريكية(  املتحدة  الواليات   كاليفورنيا، 
لهوؤالء املر�سى.
الكلمات املفتاحية: التخدير؛ اأم الدم املخية؛ ت�سيق ال�سمام املرتايل؛ قل�ص ال�سمام املرتايل؛ ديناميكا الدم؛ النتاج القلبي؛ تقرير حالة؛ عمان.
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Subarachnoid haemorrhage secondary to a ruptured intracerebral aneurysm and the sub-sequent surgery for clipping of the aneurysm is 
associated with its own inherent risks.1 However, such 
intraoperative risks are increased when the patient 
also has valvular heart disease or an associated cardiac 
comorbidity. Simultaneous consideration of both the 
cerebrovascular and cardiac conditions is particularly 
challenging for anaesthesiologists as key issues in 
the perioperative management of haemodynamic 
goals are contradictory at times and require precise 
and continuous monitoring of cardiac output and 
other related variables.1 The use of the VolumeView 
EV1000™ (Edwards Lifesciences, Irvine, California, 
USA) system in a neurosurgical setting has not yet 
been described in the literature. However, it may be 
a useful monitoring tool for goal-directed therapy in 
such cases. 
The VolumeView EV1000™ (Edwards Life-
sciences) system is a minimally invasive device that 
measures haemodynamic parameters and guides the 
use of fluids and vasopressors for patient-specific goal-
directed therapy. It provides pulse contour analysis- 
derived calibrated haemodynamic parameters—inclu- 
ding stroke volume variation (SVV), cardiac output 
and systemic vascular resistance (SVR)—as well as 
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parameters for fluid responsiveness derived from 
a transpulmonary thermodilution algorithm, such 
as the global end-diastolic volume index (GEDVI), 
extravascular lung water index (EVLWI), pulmonary 
vascular permeability index (PVPI) and contractility 
(i.e. cardiac output, stroke volume, global ejection 
fraction and SVR).2 The physiological parameters 
derived by the VolumeView EV1000™ system (Edw-
ards Lifesciences) help to determine the precise 
titration of fluid and vasopressors or inotropes; 
moreover, its accuracy is comparable to that of more 
invasive monitors.3 This case report describes the 
anaesthetic management of a patient with mitral valve 
disease who underwent a craniotomy for clipping of 
an anterior communicating artery aneurysm. The 
role of a minimally invasive cardiac output monitor 
in achieving targeted haemodynamic goals in such 
patients is highlighted.
Case Report
A 45-year-old woman presented to the Khoula 
Hospital, a tertiary care neurosurgical centre in 
Muscat, Oman, in 2016 with a sudden-onset, severe, 
holocranial headache of seven days’ duration. She 
had no history of vomiting, loss of consciousness or 
altered sensorium. However, she reported a history of 
shortness of breath on exertion (grade II dyspnoea) 
over the previous four years. On examination, she 
was found to be conscious, cooperative and alert, 
with a Glasgow coma scale score of 15, a heart rate of 
65 beats/minute and a respiratory rate of 20 breaths/
minute. Her blood pressure was 124/80 mmHg. A 
neurological examination was unremarkable and the 
headache symptoms were categorised as Hunt and 
Hess grade II.
A computed tomography (CT) scan revealed 
evidence of a subarachnoid haemorrhage (Fisher grade II) 
and an angiogram showed an anterior communicating 
artery aneurysm measuring 5.7 x 6.2 x 7.0 mm. The A1 
segment of the right anterior cerebral artery showed 
evidence of vasospasm. Transthoracic echocardio-
graphy revealed thickened calcific mitral valve leaf-
lets with mild mitral stenosis (mitral valve area: 
1.6 cm2), moderate-to-severe mitral regurgitation 
(vena contracta width: 0.5 cm; effective regurgitant 
orifice area: 0.4 cm2) with an eccentric jet hugging 
the posterior wall of the left atrium and an ejection 
fraction of 50% with adequate biventricular function. 
The pulmonary vein flow pattern on the contralateral 
side showed systolic blunting without reversal and 
the mitral regurgitation was graded as moderate-to-
severe.4 All other haematological and biochemical 
investigations were within normal limits. An urgent 
craniotomy was planned to clip the aneurysm.
In the operating room, standard monitoring 
equipment including electrocardiography, pulse 
oximetry and non-invasive blood pressure equipment 
was set up as per the recommendations of the 
American Society of Anesthesiologists.1 The baseline 
pre-induction blood pressure was 124/55 mmHg. Since 
the patient had a high perioperative cardiac risk and a 
narrow therapeutic window for fluid administration, a 
VolumeView EV1000™ (Edwards Lifesciences) arterial 
catheter with a temperature sensor was inserted in the 
right femoral artery and a triple lumen central venous 
catheter was placed in the right internal jugular vein 
while she was under sedation and local anaesthesia. 
Subsequently, the VolumeView EV1000™ (Edwards 
Lifesciences) cardiac output monitor was connected. 
Following preoxygenation, general endotracheal 
anaesthesia was administered using propofol, fentanyl, 
sevoflurane and vecuronium. A decrease in blood 
pressure following induction was managed judiciously 
with various aliquots of ephedrine.
The anaesthesia was maintained with air-
oxygen-isoflurane-propofol and supplemental doses 
of vecuronium-fentanyl, as required. The ventilation 
parameters were as follows: volume-guaranteed 
pressure-controlled ventilation, a peak inspiratory 
pressure of 20 cm, tidal volume of ~450 mL (for 
8 mL/kg of ideal body weight) and a respiratory rate 
of 14 breaths/minute (for a partial pressure of carbon 
dioxide [CO2] of 32–35 mmHg). Intraoperatively, 
judicious fluid administration (including lactated 
ringers solution and 0.9% sodium chloride) and 
inotrope/vasopressor therapy were strictly guided 
by the physiological parameters derived by the 
VolumeView EV1000™ (Edwards Lifesciences) system. 
The perioperative haemodynamic goals consisted of a 
low-to-normal SVR index and an augmented cardiac 
output. The use of colloids was avoided entirely. 
Optimum brain relaxation was achieved with 20% 
mannitol and controlled hyperventilation to maintain 
end-tidal CO2 at 30–32 mmHg. Systolic blood press-
ure was allowed to fall to 95 mmHg immediately 
before the clipping of the aneurysm. A temporary clip 
application to the feeding arteries of the aneurysm 
was not required during the surgery. Following the 
application of a permanent clip, blood pressure was 
augmented for a target mean arterial pressure (MAP) 
of 110 mmHg as the maximum upper limit using 
titrated doses of a noradrenaline infusion. However, 
this was associated with a significant fall in cardiac 
output, an increase in SVR index, a simultaneous drop 
in oxygen saturation (from 100% to 91%) with a rise in 
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the augmentation of arterial blood pressure during 
temporary clip application to curtail the impact of 
ischaemia in regions of the brain located upstream 
to the clamped artery and the suppression of cerebral 
metabolism with titrated doses of propofol or other 
volatile anaesthetic agents. Finally, the arterial blood 
pressure should be raised (systolic blood pressure: 
160–200 mmHg; MAP: >100 mmHg) following perm-
anent clip application, thereby preventing ischaemia 
in vasospastic segments.6,7 Formerly, triple-H therapy 
(i.e. hypertension, hypervolaemia and haemodilution) 
was a popular technique for managing vasospasm 
and related complications; however, hypervolaemia 
and haemodilution have since fallen out of favour due 
to their inherent complications, although induced 
hypertension (systolic blood pressure of 160–200 mmHg 
once the aneurysm is secured) is still routinely 
employed to ensure adequate cerebral blood flow.7 
Cardiac output monitoring is an important tool in 
goal-directed therapy for critically ill patients.3 While 
a pulmonary artery catheter was formerly the gold-
standard monitoring approach, its use is associated 
with various complications and increased mortality; 
accordingly, it has been progressively replaced by less 
invasive monitoring techniques.8–10 A reliable cardiac 
output monitor, ideally a minimally invasive one, could 
be of immense use for monitoring patients with cardiac 
comorbidities undergoing cerebrovascular surgery. 
Due to her pre-existing heart condition, the patient in 
the current case required precise monitoring of her left 
ventricular function. In addition, flow augmentation 
management had significant limitations due to the 
mild mitral stenosis and moderate-to-severe mitral 
regurgitation. Moreover, increasing the SVR with 
noradrenaline to achieve the target MAP adversely 
affected the cardiac output, regurgitant fraction and 
myocardial function because of the concomitant 
mitral regurgitation.
peak airway pressure (from 19 to 24 cm) and increases 
in EVLWI and GEDVI [Table 1]. 
At this point, low-dose dobutamine was 
administered at 5 μg/kg/minute to augment forward 
flow with concomitant titration of the noradrenaline 
infusion in order to attain an acceptable MAP.5 In this 
way, the patient’s blood pressure increased to 
160/82 mmHg (mean: 108 mmHg). The SVR index 
was relatively low after the induction of the anaesthesia, 
possibly due to anaesthesia-mediated vasodilation; the 
baseline SVR index was 1,680 dynes.second/cm5, which 
fell to approximately 1,460 dynes.second/cm5 after 
induction and then 1,100–1,300 dynes.second/cm5 
before the clipping of the aneurysm (normal range: 
2,000–2,400 dynes.second/cm5). Throughout the course 
of the surgery, any changes in the haemodynamic 
variables were continuously monitored, including heart 
rate, MAP, SVV, cardiac output and SVR index. The 
extubation of the patient and the postoperative course 
were uneventful. On the third postoperative day, a 
repeat CT scan was essentially normal, with evidence 
that the subarachnoid haemorrhage was resolving. 
There was no indication of a cerebral infarction 
following the surgery.
Discussion
The presence of valvular cardiac disease increases 
the anaesthetic and perioperative risks of non-
cardiac surgery.1 There are three key haemodynamic 
targets in the perioperative management of a cerebral 
aneurysm. Firstly, haemodynamic perturbations 
should be prevented when inducing anaesthesia and 
deliberate hyperventilation or hypocania should 
be avoided before the opening of the dura, as both 
of these circumstances may cause the aneurysm 
to rupture secondary to sudden changes in the 
transmural pressure gradient.6,7 Secondly, cerebral 
perfusion pressure should be preserved, including 
Table 1: Haemodynamic parameters derived by a minimally invasive cardiac output monitor* during an aneurysm 
clipping surgery for a patient with mitral valve disease








Immediately post-induction 22 690 9.2 2.3 4.8 1,460
Immediately before clipping of 
the aneurysm
28 675 8.7 2.4 4.5 1,123
Post-aneurysm clipping with 
noradrenaline infusion
17 790 14.2 3.3 2.8 3,460
Post-aneurysm clipping with 
dobutamine and noradrenaline 
infusions
13 689 11.7 2.6 4.8 2,043
SVV = stroke volume variation; GEDVI = global end-diastolic volume index; EVLWI = extravascular lung water index; PVPI = pulmonary vascular 
permeability index; CO = cardiac output; SVRI = systemic vascular resistance index.
*Using the VolumeView EV1000™ (Edwards Lifesciences, Irvine, California, USA) system.
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On the other hand, augmenting cardiac output 
using inotropes (i.e. dobutamine) could have potent-
ially caused excessive tachycardia and worsened the 
transmitral pressure gradient and pulmonary 
congestion (due to increased EVLWI).5 This could 
have led to a deterioration in oxygenation. Arguably, 
common practices to augment cerebral blood flow in 
vasospastic areas without compromising myocardial 
function and oxygenation are not themselves free of 
complications.7 As the mitral stenosis was mild, it was 
hypothesised that the patient would be better able to 
tolerate a higher heart rate rather than increased SVR. 
Hence, the aim was to perfuse the patient so as to 
augment cardiac output without excessively increasing 
the afterload, thus maintaining a low-to-normal SVR 
index and avoiding tachycardia for a target heart rate 
of 80–90 beats/minute. This was expected to maintain 
the forward flow and limit the transmitral pressure 
gradient, thus minimising the regurgitant volume 
(i.e. a lower EVLWI, GEDVI and SVV). As such, a 
reliable monitoring tool was needed to achieve these 
haemodynamic targets without adversely affecting 
cardiac output, regurgitant fraction and myocardial 
function.
Transoesophageal echocardiography is another 
useful tool for the perioperative monitoring of 
cardiac output in neurosurgical patients.11 It has been 
validated in comparison to pulmonary artery catheters 
with a good outcome.12 However, transesophageal 
echocardiography requires a skilled operator and 
its use is limited by the cost and availability of the 
equipment. The VolumeView EV1000™ (Edwards 
Lifesciences) system requires both central and arterial 
cannulation via the internal jugular and femoral 
artery, respectively. Central venous pressure does not 
adequately reflect the preload status and is therefore 
unsuitable for predicting the ventricular response to 
fluid loading; the GEDVI, a volumetric preload variable, 
more adequately reflects cardiac preload changes.13 A 
supranormal GEDVI and EVLWI indicates excessive 
fluid balance with pulmonary congestion, whereas a 
PVPI of >3 indicates increased pulmonary vascular 
permeability and thereby potentially differentiates 
cardiogenic oedema from acute respiratory distress 
syndrome.13,14 An EVLWI of >10 is associated with 
increased morbidity and mortality.14 In the present 
patient, the use of a vasopressor to increase the MAP 
after clipping resulted in a significant fall in cardiac 
output, with a concomitant increase in volume 
parameters (i.e. GEDVI and EVLWI) which suggested 
an increase in the regurgitant fraction. This was 
instantly recognised by the cardiac output monitor, 
enabling prompt use of an inodilator to augment the 
forward flow. 
Intraoperatively, due to the mild mitral stenosis 
and moderate-to-severe mitral regurgitation, the 
current patient required a comparatively high heart 
rate with a low-to-normal SVR index to augment the 
forward flow. Among the different options available to 
augment cerebral perfusion following clipping of the 
aneurysm, the continuous infusion of noradrenaline (a 
β- and α-agonist) was the preferred choice over phenyl- 
ephrine (a pure α-agonist). This was in view of the 
ability of noradrenaline to prevent the reflex brady-
cardia associated with a raised MAP.5 However, the 
physiological parameters worsened (i.e. increased 
SVR index and EVLWI with decreased cardiac output) 
following the augmentation of the MAP using a 
noradrenaline infusion alone. Initiating titrated doses 
of dobutamine resulted in a further increase in heart 
rate with a drop in SVR index. This was deemed 
appropriate in order to augment cerebral perfusion 
to the targeted level and was subsequently reflected 
in the physiological parameters (i.e. a decreased SVR 
index and EVLWI with increased cardiac output). The 
fall in the SVR index probably resulted in a reduction 
in the regurgitant fraction of the mitral regurgitation 
and augmentation of the cardiac output following the 
dobutamine infusion. Although temporary clipping 
was not necessary, dobutamine and noradrenaline 
infusions were titrated to achieve augmented perfusion 
as well as an appropriate MAP postoperatively.
Conclusion
Conflicting haemodynamic goals can complicate 
the anaesthetic management of patients with 
mitral valve diseases undergoing surgical clipping 
of a cerebral aneurysm. Minimally invasive cardiac 
output monitoring devices, such as the VolumeView 
EV1000™ (Edwards Lifesciences) system, are useful in 
such situations to aid in the accurate titration of fluids 
and inotropes/vasopressors according to myocardial 
performance, thus greatly enhancing patient safety 
while under anaesthesia.
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